摘要
目的分析赤峰地区蒙古族冠心病患者CYP2C19基因多态性分布状况。方法选取2018年3-12月于该院确诊为冠心病并行经皮冠状动脉介入术治疗的患者558例为研究对象,其中蒙古族患者299例为研究组,汉族患者259例为对照组。抽取两组患者的外周血2 mL,提取基因组DNA,采用实时荧光定量PCR方法检测CYP2C19基因多态性,比较两组间CYP2C19基因型、代谢型分布情况。结果研究组患者CYP2C19*1/*1、*1/*2、*2/*3型所占比例均高于对照组(P<0.05);两组CYP2C19*1/*3、*2/*2、*3/*3型所占比例比较,差异无统计学意义(P>0.05)。研究组中间代谢型和慢代谢型基因所占比例低于对照组(P<0.05),快代谢型基因所占比例高于对照组(P<0.05)。结论赤峰地区蒙古族冠心病患者CYP2C19基因存在不同基因型和代谢型,与汉族冠心病患者间存在差异。掌握CYP2C19基因的多态性分布情况对冠心病患者抗凝药物的选择具有重要意义。
Objective To explore the distribution of CYP2C19 gene polymorphism in Mongolian coronary heart disease(CHD)patients in Chifeng area.Methods A total of 558 patients diagnosed as CHD and treated with percutaneous coronary intervention in the hospital from March to December 2018 were selected as the study objects,including 299 Mongolian patients as the research group and 259 Han patients as the control group,2 mL peripheral blood samples were collected from the two groups,genomic DNA was extracted,and the CYP2C19 gene polymorphism was detected by real-time fluorescent quantitative PCR.The distribution of CYP2C19 genotypes and metabotypes were compared between the two groups.Results The proportion of patients with CYP2C19*1/*1,*1/*2,*2/*3 types in the research group were higher than those in the control group(P<0.05);There were no significant differences in the proportion of CYP2C19*1/*3,*2/*2,*3/*3 types(P>0.05).The proportion of intermediate metabolized and slow metabolized genes in the research group were lower than those in the control group(P<0.05),and the proportion of fast metabolized genes was higher than that in the control group(P<0.05).Conclusion There are different genotypes and metabotypes of CYP2C19 gene in Mongolian patients with CHD in Chifeng area,which are different from those in Han patients.It is of great significance to know the distribution of CYP2C19 gene polymorphism for the selection of anticoagulants in patients with CHD.
作者
陈晓梅
李树敏
韩旭晨
霍昱吉
李静
陈士萍
CHEN Xiaomei;LI Shumin;HAN Xuchen;HUO Yuji;LI Jing;CHEN Shiping(Affiliated Hospital of Chifeng University,Department of Clinical Laboratory,Chifeng,Inner Mongolia 024005,China;Affiliated Hospital of Chifeng University,Department of Cardiology,Chifeng,Inner Mongolia 024005,China)
出处
《检验医学与临床》
CAS
2020年第5期586-588,592,共4页
Laboratory Medicine and Clinic
基金
内蒙古自治区高等学校科学技术研究项目（NJZY19218）
